A NEW drug developed to combat diabetes and obesity melts fat at double the rate of other GLP-1 drugs, scientists say. The ...

Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...

USA: A recent study published in Diabetes, Obesity and Metabolism has reported that the use of glucagon-like peptide-1 ...

The findings suggest that while GLP-1 RAs may slightly raise the risk of developing diabetic retinopathy, they do not ...

GLP-1 receptor agonists may outperform metformin in lowering the risk for dementia, particularly Alzheimer’s disease and other nonvascular types, in patients with type 2 diabetes.

For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a ...

Overweight patients waiting for operations could safely use a particular type of weight-loss treatment to reduce the risk of ...

Older adults with diabetes using GLP-1 receptor agonist medications may face increased risk of serious eye conditions, study ...

If you’ve been looking into weight loss options, you may have stumbled upon GLP-1 receptor agonists (GLP-1 RAs). Originally developed to help people with type 2 diabetes control their blood ...

In this retrospective study, patients who started a GLP-1 agonist experienced significant declines in hidradenitis ...

GLP-1 RAs were associated with positive effects on intracranial hypertension management, including reduced symptoms and treatment burden.

Kosuke Inoue, MD, PhD, from Kyoto University in Japan, and colleagues compared the effect of GLP-1 RAs to DPP4is as second-line therapy for type 2 diabetes on the risk for dementia in a target ...